Abstract
Cachexia, a complex metabolic syndrome, is characterized by involuntary weight loss along with muscle wasting and fat depletion leading to poor quality of life of patients. About 80% of pancreatic cancer patients exhibit cachectic phenotype at the time of diagnosis. Here, we present the several molecular and physiological parameters, which we utilize to study the pancreatic cancer-induced cachexia in in vitro models and preclinical mice models of pancreatic cancer. We have described myotube and adipocyte-based in vitro models of muscle and fat wasting, including methods of cell culture, differentiation, and treatment with cancer cell-conditioned medium. Furthermore, we have explained the methods of evaluation of key cachectic markers for muscles. Next, we have detailed the orthotopic implantation mouse models of pancreatic cancer and evaluation of different physiological parameters, including body weight, food intake, body composition analysis, glucose tolerance test, insulin resistance test, grip strength measurement, and rotarod performance test. We have also explained morphological parameters and molecular markers to evaluate the muscle wasting in pancreatic cancer-induced cachexia.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tisdale MJ (2002) Cachexia in cancer patients. Nat Rev Cancer 2:862–871
Lok C (2015) Cachexia: The last illness. Nature 528:182–183
Johns N, Stephens NA, Fearon KC (2013) Muscle wasting in cancer. Int J Biochem Cell Biol 45:2215–2229
Tuca A, Jimenez-Fonseca P, Gascon P (2013) Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol 88:625–636
Argiles JM, Fontes-Oliveira CC, Toledo M, Lopez-Soriano FJ, Busquets S (2014) Cachexia: a problem of energetic inefficiency. J Cachexia Sarcopenia Muscle 5:279–286
Shukla SK, Gunda V, Abrego J, Haridas D, Mishra A, Souchek J et al (2015) MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism. Oncotarget 6:19118–19131
Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E et al (2017) MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer. Cancer Cell 32:71–87 e7
Tadros S, Shukla SK, King RJ, Gunda V, Vernucci E, Abrego J et al (2017) De novo lipid synthesis facilitates gemcitabine resistance through endoplasmic reticulum stress in pancreatic cancer. Cancer Res 77:5503–5517
Gunda V, Souchek J, Abrego J, Shukla SK, Goode GD, Vernucci E et al (2017) MUC1-mediated metabolic alterations regulate response to radiotherapy in pancreatic cancer. Clin Cancer Res 23:5881–5891
Chaika NV, Gebregiworgis T, Lewallen ME, Purohit V, Radhakrishnan P, Liu X et al (2012) MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc Natl Acad Sci U S A 109:13787–13792
Shukla SK, Gebregiworgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P et al (2014) Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab 2:18
Shukla SK, Dasgupta A, Mehla K, Gunda V, Vernucci E, Souchek J et al (2015) Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. Oncotarget 6:41146–41161
Kotler DP (2000) Cachexia. Ann Intern Med 133:622–634
Shukla SK, Kumar V (2012) Hepatitis B virus X protein and c-Myc cooperate in the upregulation of ribosome biogenesis and in cellular transformation. FEBS J 279:3859–3871
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Shukla, S.K., Dasgupta, A., Mulder, S.E., Singh, P.K. (2019). Molecular and Physiological Evaluation of Pancreatic Cancer-Induced Cachexia. In: Su, G. (eds) Pancreatic Cancer. Methods in Molecular Biology, vol 1882. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8879-2_28
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8879-2_28
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8878-5
Online ISBN: 978-1-4939-8879-2
eBook Packages: Springer Protocols